YU-SHAN HUANGHSIN-YUN SUNSUI-YUAN CHANGYU-CHUNG CHUANGSu, Yi-ChingYi-ChingSuLiu, Wen-ChunWen-ChunLiuCHIEN-CHING HUNG2022-12-292022-12-29202209248579https://scholars.lib.ntu.edu.tw/handle/123456789/626821Data on the effectiveness of tenofovir alafenamide (TAF) against lamivudine-resistant (LAM-R) hepatitis B virus (HBV) among patients co-infected with human immunodeficiency virus (HIV) and HBV are limited.enAntiviral resistance; Hepatitis B virus envelope antigen; Hepatitis B virus surface antigen; Nucleos(t)ide analogue; Seroconversion; Tenofovir alafenamide[SDGs]SDG3Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virusjournal article10.1016/j.ijantimicag.2022.106682362799762-s2.0-85142124735https://api.elsevier.com/content/abstract/scopus_id/85142124735